JPRN-jRCT2080222639已完成3 期
A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- Cytologically or histologically confirmed advanced gastric or GEJ adenocarcinoma that is metastatic or locally advanced and unresectable.
- •- Failed treatment with one regimen containing at least a platinum/fluoropyrimidine doublet for unresectable or metastatic disease.
- •- ECOG performance status of 0 or 1
排除标准
- •- Prior taxanes in the neoadjuvant or adjuvant setting with progression occurring within 6 months of completion of taxane therapy; or any taxanes in the metastatic setting.
- •- Major surgery within 4 weeks prior to randomization.
- •- Any known symptomatic brain metastases requiring steroids.
研究者
相似试验
已完成
3 期
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerGastric CancerGastroesophageal Junction CancerNCT02178956Sumitomo Pharma America, Inc.714
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.EUCTR2016-001627-31-BEBoston Biomedical, Inc.1,250
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001627-31-NLSumitomo Dainippon Pharma Oncology, Inc.1,250
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.EUCTR2016-001627-31-ESBoston Biomedical, Inc.1,253
已完成
3 期
A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)Colorectal cancerbowel cancer10017991NL-OMON55360Boston Biomedical, Inc49